Altre lingue Theravance Biopharma, Inc.

Azioni

TBPH

KYG8807B1068

Tempo reale stimato Cboe BZX Altri mercati azionari 21:07:47 26/04/2024			Variaz. 5gg	Var. 1 gen.
9,15 ^USD	+0,11%		-1,77%	-18,37%

12/04	Aggiornamento settoriale: titoli del settore sanitario in ribasso venerdì pomeriggio	MT
12/04	Le azioni di Theravance Biopharma salgono dopo che BTIG ha iniziato la copertura con un rating buy (acquistare)	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sector Update: Health Care Stocks Lower Friday Afternoon	12/04
Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	12/04
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024	10/04
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	01/03
Theravance Bio: Q4 Earnings Snapshot	26/02
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q4 Revenue $17.6M, vs. Street Est of $17.6M	26/02
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	26/02
Theravance Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Theravance Biopharma to Participate in an Upcoming Investor Conference	22/02
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024	14/02
Theravance Biopharma Shares Drop Pre-Bell as Phase 4 Study of Lung Disease Treatment Fails to Meet Primary Endpoint	05/01
Top Premarket Decliners	05/01
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)	05/01
Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease	05/01
Theravance Biopharma, Inc.'s Equity Buyback announced on September 19, 2022, has closed.	01/01
Theravance Biopharma : Material Event - Form 8-K	28/12
Theravance Biopharma Announces Appointment of Jeremy Grant to Board of Directors	21/12
Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director	21/12
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors	21/12
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference	18/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Theravance Biopharma, Inc.

Azioni

TBPH

KYG8807B1068

Altre lingue

Filtri